Description
A group I PAK inhibitor (IC50s = 8.25, 39.5, and 55.3 nM for PAK1, PAK2, and PAK3, respectively); selective for group I PAKs over PAK4 (IC50 = 779 nM); reverses decreases in the mean density of apical dendritic spines in the temporal cortex in the Fmr1-/- mouse model of fragile X syndrome at 20 mg/kg; completely abolishes audiogenic seizures, hyperactivity, and stereotypical movements in Fmr1-/- mice at 30 mg/kg; events adolescent cortical dendritic spine loss and rescues prepulse inhibition deficits in a Disc1 knockdown mouse model of schizophrenia,
Formal name: 6-(2,4-dichlorophenyl)-8-ethyl-2-[[3-fluoro-4-(1-piperazinyl)phenyl]amino]-pyrido[2,3-d]pyrimidin-7(8H)-one
Synonyms:
Molecular weight: 513.4
CAS: 1232030-35-1
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|Other Serine/Threonine Kinases||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Neuroscience|Behavioral Neuroscience|Schizophrenia & Psychosis||Research Area|Neuroscience|Neuroprotection
